Talk:Allylisopropylacetylurea
 |
This page has not been fully approved by the PsychonautWiki administrators. It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards. |
| Summary sheet: Allylisopropylacetylurea |
Template:SubstanceBox/Allylisopropylacetylurea
History and culture
Allylisopropylacetylurea or Apronal is a hypnotic sedative made by Roche in 1926. Due to several side effects, its use has been discontinued except in some countries.
Chemistry
 |
This chemistry section is incomplete. You can help by adding to it. |
Pharmacology
 |
This pharmacology section is incomplete. You can help by adding to it. |
Although not belonging to the barbiturate class, it is structurally similar to barbituric acid and is known to have a similar mechanism of action.
Subjective effects
 |
This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it. |
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects 
- If applicable, a brief paragraph summary of the substance's physical effects may be included here. You may select physical effects to add below here.
Visual effects 
-
If applicable, a brief paragraph summary of the substance's visual effects may be included here.
You may select visual effects to add below here.
Enhancements
Distortions
Geometry
If applicable, a brief paragraph summary describing the visual geometry produced by the substance may be included here.
Hallucinatory states
If applicable, a brief summary of the substance's visual effects profile may be written here.
Cognitive effects 
- If applicable, a brief paragraph summary of the substance's cognitive effects may be included here. You may select from a list of cognitive effects to add below here.
Auditory effects 
- If applicable, a brief paragraph summary of the substance's auditory effects may be included here. You may select from a list of auditory effects to add below here.
Multi-sensory effects 
- If applicable, a brief paragraph summary of the substance's multisensory effects may be included here. You may select from a list of multisensory effects to add below here.
Transpersonal effects 
- If applicable, a brief paragraph summary of the substance's transpersonal effects may be included here. You may select from a list of transpersonal effects to add below here.
Experience reports
There are currently 0 experience reports describing the effects of this substance in our experience index. You can also submit your own experience report using the same link.
Additional experience reports can be found here:
Toxicity and harm potential
 |
This toxicity and harm potential section is a stub. As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. |
It is strongly recommended that one use harm reduction practices when using this substance. At typical doses, thrombocytopenic purpura is the most representative adverse effect, and the incidence of other platelet-related side effects is also high. Consequently, its use has been discontinued in the United States since 1938. Meanwhile, in Europe, due to similar adverse effects, the use of alternative ingredients has been recommended since 1942, and currently, no marketed products exist.This ingredient shares a mechanism similar to barbiturates, and there have been fatal cases due to excessive central nervous system depression following high-dose administration. Furthermore, due to its mechanism and the caffeine present in most combination products, dependency can develop with repeated use. Like barbiturates, it suppresses the central nervous system and has a sedative effect, potentially causing drowsiness.Since its use was discontinued in Europe and the United States after the 1950s, fewer adverse effects have been reported compared to other drugs, so caution is advised. Subsequent adverse effect reports have mostly originated from Japan. Japan and Korea remain the only countries where products containing this ingredient are still widely marketed. In Korea, it is sold in combination tablets mixed with other ingredients to eliminate its psychotropic effects, but it is not as widely used as in Japan.
Effects begin to appear at doses of 300mg or higher. LD50 is 1050mg/kg when administered orally to rats.
Tolerance and addiction potential
Dangerous interactions
|
This dangerous interactions section is a stub. As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it. |
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Legal status
 |
This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
In South Korea, single-ingredient formulations are classified as psychotropic drugs, but no such single-ingredient products are currently sold. However, a generic version with an identical combination to the Japanese medication “EVE QUICK” is marketed for menstrual pain relief. That is, this medication is typically used only in South Korea and Japan. Currently, it is not produced as a single-ingredient formulation; only medications combined with substances such as caffeine and ibuprofen are sold over-the-counter.
See also
External links
(List along order below)
- Allylisopropylacetylurea (NamuWiki)
- Allylisopropylacetylurea (National Library of Medicine)
- Allylisopropylacetylurea (WikiPedia)
Literature
- APA formatted reference
Please see the citation formatting guide if you need assistance properly formatting citations.
References
History and culture
Allylisopropylacetylurea or apronal is a hypnotic sedative made by Roche in 1926. Due to several side effects, its use has been discontinued except in some countries.
Chemistry
|
This chemistry section is incomplete. You can help by adding to it. |
Pharmacology
|
This pharmacology section is incomplete. You can help by adding to it. |
Although not belonging to the barbiturate class, it is structurally similar to barbituric acid and is known to have a similar mechanism of action.
Subjective effects
|
This subjective effects section is a stub. As such, it is still in progress and may contain incomplete or wrong information. You can help by expanding or correcting it. |
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
- If applicable, a brief paragraph summary of the substance's physical effects may be included here. You may select physical effects to add below here.
Visual effects
-
If applicable, a brief paragraph summary of the substance's visual effects may be included here.
You may select visual effects to add below here.
Enhancements
Distortions
Geometry
If applicable, a brief paragraph summary describing the visual geometry produced by the substance may be included here.
Hallucinatory states
If applicable, a brief summary of the substance's visual effects profile may be written here.
Cognitive effects
- If applicable, a brief paragraph summary of the substance's cognitive effects may be included here. You may select from a list of cognitive effects to add below here.
Auditory effects
- If applicable, a brief paragraph summary of the substance's auditory effects may be included here. You may select from a list of auditory effects to add below here.
Multi-sensory effects
- If applicable, a brief paragraph summary of the substance's multisensory effects may be included here. You may select from a list of multisensory effects to add below here.
Transpersonal effects
- If applicable, a brief paragraph summary of the substance's transpersonal effects may be included here. You may select from a list of transpersonal effects to add below here.
Experience reports
There are currently 0 experience reports describing the effects of this substance in our experience index. You can also submit your own experience report using the same link.
Additional experience reports can be found here:
Toxicity and harm potential
|
This toxicity and harm potential section is a stub. As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. |
It is strongly recommended that one use harm reduction practices when using this substance. At typical doses, thrombocytopenic purpura is the most representative adverse effect, and the incidence of other platelet-related side effects is also high. Consequently, its use has been discontinued in the United States since 1938. Meanwhile, in Europe, due to similar adverse effects, the use of alternative ingredients has been recommended since 1942, and currently, no marketed products exist.This ingredient shares a mechanism similar to barbiturates, and there have been fatal cases due to excessive central nervous system depression following high-dose administration. Furthermore, due to its mechanism and the caffeine present in most combination products, dependency can develop with repeated use. Like barbiturates, it suppresses the central nervous system and has a sedative effect, potentially causing drowsiness.Since its use was discontinued in Europe and the United States after the 1950s, fewer adverse effects have been reported compared to other drugs, so caution is advised. Subsequent adverse effect reports have mostly originated from Japan. Japan and Korea remain the only countries where products containing this ingredient are still widely marketed. In Korea, it is sold in combination tablets mixed with other ingredients to eliminate its psychotropic effects, but it is not as widely used as in Japan. The median lethal dose of this drug is 1050 mg/kg when administered orally to rats.
Lethal dosage
Effects begin to appear at doses of 300mg or higher.
Tolerance and addiction potential
Dangerous interactions
|
This dangerous interactions section is a stub. As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it. |
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Legal status
|
This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
In South Korea, single-ingredient formulations are classified as psychotropic drugs, but no such single-ingredient products are currently sold. However, a generic version with an identical combination to the Japanese medication “EVE QUICK” is marketed for menstrual pain relief. That is, this medication is typically used only in South Korea and Japan. Currently, it is not produced as a single-ingredient formulation; only medications combined with substances such as caffeine and ibuprofen are sold over-the-counter.
See also
External links
(List along order below)
Literature
- APA formatted reference
Please see the citation formatting guide if you need assistance properly formatting citations.